Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes

Biplab Dasgupta, Wen Li, Arie Perry, David H. Gutmann

Research output: Contribution to journalArticlepeer-review

93 Scopus citations

Abstract

Children with the tumor predisposition syndrome, neurofibromatosis 1 (NF1), develop optic pathway gliomas. The NF1 gene product, neurofibromin, functions as a negative regulator of RAS, such that NF1 inactivation results in RAS hyperactivation. Recent studies have highlighted the divergent biological and biochemical properties of the various RAS isoforms, which prompted us to examine the consequence of Nfl inactivation in astrocytes on RAS isoform activation in vitro and in vivo. In this report, we show that only K-RAS is activated in Nf1-/- astrocytes and that activation of K-RAS, but not H-RAS, accounts for the proliferative advantage and abnormal actin cytoskeleton-mediated processes observed in Nf1-/- astrocytes in vitro. Moreover, dominant inhibitory K-RAS corrects these abnormalities in Nf1-/- astrocytes in vitro. Lastly, we show that Nf1+/- mice with astrocyte-specific activated K-RAS expression in vivo develop optic pathway gliomas, similar to our previously reported Nf1+/- mice with astrocyte Nf1 inactivation. Collectively, our results show that K-RAS is the primary target for neurofibromin GTPase-activating protein activity in vitro and in vivo and that K-RAS activation in astrocytes recapitulates the biochemical, biological, and tumorigenic properties of neurofibromin loss.

Original languageEnglish
Pages (from-to)236-245
Number of pages10
JournalCancer research
Volume65
Issue number1
StatePublished - Jan 1 2005

Fingerprint

Dive into the research topics of 'Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes'. Together they form a unique fingerprint.

Cite this